Tag Archives: Anaptys Bio
Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More
If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook. This week […]
Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Adagio Therapeutics, Adimab, ALX Oncology, Amgen, Anaptys Bio, Andrew Partridge, Arctic Bio, atezolizumab (Tecentriq), Atox Bio, BeiGene, Berkeley Lights, bevacizumab, Biocon, Biotech, Biotech IPOs, Blueprint Medicines, Brittany Bradrick, C4 Therapeutics, cancer, Cancer Drugs, cancer immunotherapy, Cerevel Therapeutics, Chemotherapy, Christopher Slapak, Citius Pharmaceuticals, Claude Knopf, COVID-19, cytodyn, deals, Dennis Mulroy, Dewpoint Therapeutics, Equillium, Eric Loumeau, Eyepoint Pharmaceuticals, Flagship Pioneering, Gilead Sciences, Glympse Bio, Guillaume Pfefer, guselkumab, HIV, Hp Wild Holding, ImCheck Therapeutics, Immunotherapy, Imvax, infectious diseases, Inventiva, investing, Jay Duker, Johnson & Johnson, Jolie Siegel, Kathleen Tregoning, Keith Sullivan, Kiadis Pharma, kidney failure, Kintai Therapeutics, Kronos Bio, leronlimab, Life Sciences, Liver Disease, Mallinckrodt Pharmaceuticals, Merck, ModeRNA, molluscum contagiosum, Morningside Ventures, Myron Czuczman, Nagesh Mahanthappa, National Venture Capital Association, necrotizing soft tissue infection, Neuronetics, New England Journal of Medicine, Nkarta, nonalcoholic steatohepatitis, Norbert Bischofberger, Novartis, Ophthalmology, Ovarian Cancer, Pandion Therapeutics, Phathom Pharmaceuticals, PitchBook, Poseida Therapeutics, pralsetinib, Ray Barlow, Relay Therapeutics, reltecimod, Roche, Scholar Rock, startups, terlipressin, Todd Branning, Tony Kingsley, Turning Point Therapeutics, Vaccine, Verrica Pharmaceuticals, ViaCyte, Vor BioPharma, William McKee | Comments Off on Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & MoreBio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More
During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the center of a patent dispute between the Foster City, CA, drug maker and the […]
Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged A2 Therapeutics, Abraham Scaria, Acadia Pharmaceuticals, ADHD, Aerie Pharmaceuticals, Alzheimer's disease, Anaptys Bio, Antibiotic, Arkuda Therapeutics, Ashley Winslow, AstraZeneca, atopic dermatitis, Biogen, Biotech, Biouniversa, Centers for Disease Control and Prevention, Checkmate Pharmaceuticals, China, clinical trials, CRISPR, Dauntless Pharmaceuticals, David Altarac, David Hollander, deals, Dementia, Drug Delivery, eGenesis, EIP Pharma, Eli Kalif, Entasis therapeutics, eosinophilic asthma, Epizyme, etokimab, FDA, Foundation Medicine, Galera Therapeutics, Gene editing, Gilead Sciences, Halozyme Therapeutics, HIV, Infection, Inflammation, Intrepida Bio, investing, IVERIC bio, Kleem Chaudhary, Life Sciences, MD Anderson Cancer Center in Houston, Medical Device, neflamapimod, Odylia Therapeutics, Pancreatic Cancer, Pharmakon Advisors, Ponni Subbiah, President Trump, RedHill BioPharma, Regenerative Medicine, RNA editing, Robin Isaacs, RoboticsAI, Royalty Pharma, Samsung Bioepis, Sangamo Therapeutics, Section 32, Shape Therapeutics, Shire, Stada Arzneimittel, startups, Stephen Hahn, Steve Kafka, Stryker, Sung Lee, SuperNus Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Third Rock Ventures, University of Pennsylvania, University of Texas MD Anderson Cancer Center, Vertex Pharmaceuticals | Comments Off on Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & MoreWest Coast Bio Roundup: Illumina, CRISPR, Orexigen, Ambry & More
El Niño-driven storms returned to California this week to fill up reservoirs and snarl commutes, although we’ve got nothing to compare with what’s happening down South. A few biotech parades were rained on out West. The two rival parties battling for CRISPR patent rights tried to undermine each other’s cases, filing documents to kick off […]
Posted in National blog main, National top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged "Visionary Kids: Steve Jobs", Ambry Genetics, Anaptys Bio, Aspyrian Therapeutics, B cells, Berkeley, Biotech, Broad Institute of Harvard and MIT, change, Charles Dunlop, Contrave, CRISPR, El Nino, Five Prime Therapeutics, FP-1039, Francis deSou, GlaxoSmithKline, Grail, Helix, Illumina, ImmuSoft, JAMA, Jay Flatley, Joshua Sharfstein, Life Sciences, Liquid Biopsy, NuVasive, Orexigen, Rain, Tizona Therapeutics, University of California, Xoma | Comments Off on West Coast Bio Roundup: Illumina, CRISPR, Orexigen, Ambry & MoreSan Diego’s Biotech Leaders of Tomorrow: ‘We Are the Wildcatters’
(Xconomy contributor Juliet Preston helped pull this story together) One more sign that the U.S. life sciences industry is in upheaval became evident last month, when the Chicago real estate group Jones Lang LaSalle issued its 2012 report on life sciences clusters. The study revealed that biomedical clusters in several smaller U.S. cities are gaining […]
Posted in National blog main, National top stories, San Diego, San Diego blog main, San Diego top stories | Tagged Advanced Proteomics, Algae-based Biofuels, Anaptys Bio, Biocom, Bioinformatics, Biologics, Biomedical Diagnostics, BioNano Genomics, Biotech, cancer, Carmine Stengone of Avelas Bioscience, Cellana, Chris Hibberd, cleantech, Cypher Genomics Ashley Van Zeeland, David Nelson, David Urso, Devices, Digital Healths., Domain Ventures, Drugs, Eclipse Therapeutics, Entrepreneurship, Epic Sciences, Erik Holmlin, Financing, funding, General Atomics, Genetic Diagnostics, Genoa Pharmaceuticals, Genomics, Hamza Suria, Healthtech, Industrial Biotechnology, innovation, Jennifer Cayer, Joe Panetta, Keith Murphy, Life Sciences, Martin Sabarsky, Matt Dixon, Michael Kamdar, Michelle M. Hanna, MoneyTree Survey, Nimesh Shah, Organova, people, Peter Chu, Peter Klemm, Rempex Therapeutics, RiboMed Biotechnologies, Sapphire Energy, Scott Forrest, SkinMedica, startups, Stem Cell Therapies, Synthetic Genomics, Tech, Technology Clusters, Ted Ebel, The Scripps Research Institute, Tioga Pharmaceuticals, Todd Dickinson, Verenium, Wireless Health | Comments Off on San Diego’s Biotech Leaders of Tomorrow: ‘We Are the Wildcatters’Avalon Ventures, Coming Off Zynga Investment, Raising 10th Fund
Venture investing in the life sciences has been declining over the past year or so, along with a contraction in the number of VC firms that are actively investing. Yet San Diego’s Avalon Ventures, which also has a strong presence in Boston, seems to be running contrary to the industry’s overall trend. The venture firm—which […]
Posted in Boston blog main, Boston top stories, National blog main, National top stories, San Diego, San Diego blog main, San Diego top stories | Tagged Anaptys Bio, app, Avalon Ventures, Awarepoint, Backupify, Brady Bohrmann, Cardeas Pharma, Court Turner, deals, funding, innovation, Innovation Economy, Internet, IT, Jay Lichter, Kevin Kinsella, Kinvey, Life Sciences, Mark Pincus, MOGL, people, Rich Levandov, Software, startups, Steve Tomlin, VC, Venture Capital, Venture Fund-Raising, Web, Zynga | Comments Off on Avalon Ventures, Coming Off Zynga Investment, Raising 10th FundArchives
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- July 2006
- June 2006
- April 2006
- March 2006
- February 2006
- January 2006
- December 2005
- October 2005
- September 2005
- August 2005
- July 2005
- June 2005
- May 2005
- April 2005
- March 2005
- February 2005
- January 2005
- December 2004
- September 2004
- June 2004
- May 2004
- March 2004
- February 2004
- January 2004
- December 2003
- June 2003
- May 2003
- March 9
Meta